Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

Company Overview - Regencell Bioscience (NASDAQ: RGC) has a market capitalization of nearly $12 billion and has seen a stock price increase of 21,000% over the past year, starting as a penny stock [1] - The company is described as an early-stage bioscience firm focused on researching drugs, but it has not yet developed any marketable products [2][4] Research Focus - Regencell has been examining traditional Chinese medicine (TCM) since its establishment in 2014, yet it still lacks a patented drug [4] - The company has not generated any revenue from product sales, highlighting the high-risk nature of its business model [5] Investment Risks - The investment in Regencell is considered high-risk due to the absence of a product and the speculative nature of early-stage bioscience investments [6][7] - Investors are advised to consider more established pharmaceutical companies with proven track records, such as Pfizer, which has a large portfolio of patent-protected drugs [7]